The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Open accessAbstract
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD).In vitro data demonstrate that nintedanib inhibits several steps in the initiation and progression of lung fibrosis, including the release of pro-inflammatory and pro-fibrotic mediators, migration and differentiation of fibrocytes and fibroblasts, and deposition of extracellular matrix. Nintedanib also inhibits the proliferation of vascular cells. Studies in animal models with features of fibrosing ILDs such as IPF, SSc-ILD, rheumatoid arthritis-ILD, hypersensitivity pneumonitis and silicosis demonstrate that nintedanib has anti-fibrotic activity irrespective of the trigger for the lung pathology. This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease
Liu, F., Wang, L., Qi, H., Wang, J., Wang, Y., Jiang, W., Xu, L., Liu, N., & Zhuang, S. (2017) · Clinical Science · doi:10.1042/cs20170134 · Cited by 76
RetractedEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Signal transduction by lymphocyte antigen receptors
Weiss, A., & Littman, D. R. (1994) · Cell · doi:10.1016/0092-8674(94)90334-4 · Cited by 2,089
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationLeung, C. C., Yu, I. T. S., & Chen, W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60235-9 · Cited by 1,193
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Straus, D. (1992) · Cell · doi:10.1016/0092-8674(92)90428-f · Cited by 1,034
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Self-citationMatrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction
Huang, X., Yang, N., Fiore, V. F., Barker, T. H., Sun, Y., Morris, S. W., Ding, Q., Thannickal, V. J., & Zhou, Y. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0050oc · Cited by 530
Epithelial Origin of Myofibroblasts during Fibrosis in the Lung
Willis, B. C., duBois, R. M., & Borok, Z. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-004tk · Cited by 500
Barber, E. K., Dasgupta, J. D., Schlossman, S. F., Trevillyan, J. M., & Rudd, C. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3277 · Cited by 452
New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
Fernandez, I. E., & Eickelberg, O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61144-1 · Cited by 437
Fernández Pérez, E. R., Swigris, J. J., Forssén, A. V., Tourin, O., Solomon, J. J., Huie, T. J., Olson, A. L., & Brown, K. K. (2013) · Chest · doi:10.1378/chest.12-2685 · Cited by 389
Role of Lung Pericytes and Resident Fibroblasts in the Pathogenesis of Pulmonary Fibrosis
Hung, C., Linn, G., Chow, Y.-H., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A., Gharib, S. A., Schnapp, L. M., & Duffield, J. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2297oc · Cited by 385
Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis
Andersson-Sjöland, A., de Alba, C. G., Nihlberg, K., Becerril, C., Ramírez, R., Pardo, A., Westergren-Thorsson, G., & Selman, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.02.012 · Cited by 360
What's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
Self-citationIdiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Maher, T. M., Wells, A. U., & Laurent, G. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00069307 · Cited by 341
Self-citationFibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Self-citationSerum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G. B., Flaherty, K. R., Olschewski, M., Rottoli, P., & Müller-Quernheim, J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1201oc · Cited by 328
Heterogeneous Increase in CD34-positive Alveolar Capillaries in Idiopathic Pulmonary Fibrosis
Ebina, M., Shimizukawa, M., Shibata, N., Kimura, Y., Suzuki, T., Endo, M., Sasano, H., Kondo, T., & Nukiwa, T. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1111oc · Cited by 320
Prevalence and prognosis of unclassifiable interstitial lung disease
Ryerson, C. J., Urbania, T. H., Richeldi, L., Mooney, J. J., Lee, J. S., Jones, K. D., Elicker, B. M., Koth, L. L., King, T. E., Wolters, P. J., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00131912 · Cited by 310
Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Y., Kim, D. S., Shim, T. S., Lim, C.-M., Do Lee, S., Koh, Y., Kim, W. S., Kim, W. D., Lee, J. S., Travis, W. D., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-331oc · Cited by 308
The central role of T cells in rheumatoid arthritis.
Cope, A. P., Schulze‐Koops, H., & Aringer, M. (2007) · PubMed · Cited by 300
New Mechanisms of Pulmonary Fibrosis
Strieter, R. M., & Mehrad, B. (2009) · Chest · doi:10.1378/chest.09-0510 · Cited by 284
Cellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277
Characterisation of patients with interstitial pneumonia with autoimmune features
Oldham, J. M., Adegunsoye, A., Valenzi, E., Lee, C., Witt, L., Chen, L., Husain, A. N., Montner, S., Chung, J. H., Cottin, V., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01565-2015 · Cited by 275
Hostettler, K. E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., et al. (2014) · Respiratory Research · doi:10.1186/s12931-014-0157-3 · Cited by 258
Predictors of mortality in pulmonary sarcoidosis
Kirkil, G., Lower, E. E., & Baughman, R. P. (2018) · Chest · doi:10.1016/j.chest.2017.07.008 · Cited by 243
T cells in systemic sclerosis: a reappraisal
O'Reilly, S., Hugle, T., & van Laar, J. M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes090 · Cited by 218
Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Zamora‐Legoff, J. A., Krause, M. L., Crowson, C. S., Ryu, J. H., & Matteson, E. L. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39971 · Cited by 215
Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Schupp, J. C., Binder, H., Jäger, B., Cillis, G., Zissel, G., Müller-Quernheim, J., & Prasse, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116775 · Cited by 204
Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207109 · Cited by 196
Self-citationMoore, O. A., Goh, N., Corte, T., Rouse, H., Hennessy, O., Thakkar, V., Byron, J., Sahhar, J., Roddy, J., Gabbay, E., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes289 · Cited by 192
Flaherty, K. R., Brown, K. K., Wells, A. U., Clerisme-Beaty, E., Collard, H. R., Cottin, V., Devaraj, A., Inoue, Y., Le Maulf, F., Richeldi, L., et al. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000212 · Cited by 184
Self-citationHuang, J., Maier, C., Zhang, Y., Soare, A., Dees, C., Beyer, C., Harre, U., Chen, C.-W., Distler, O., Schett, G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210823 · Cited by 182
Self-citationPhase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Mross, K., Stefanic, M., Gmehling, D., Frost, A., Baas, F., Unger, C., Strecker, R., Henning, J., Gaschler-Markefski, B., Stopfer, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0694 · Cited by 171
p56lck interacts via its src homology 2 domain with the ZAP-70 kinase.
Duplay, P., Thome, M., Hervé, F., & Acuto, O. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1163 · Cited by 159
Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung
Sava, P., Ramanathan, A., Dobronyi, A., Peng, X., Sun, H., Ledesma-Mendoza, A., Herzog, E. L., & Gonzalez, A. L. (2017) · JCI Insight · doi:10.1172/jci.insight.96352 · Cited by 150
Effects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 141
Self-citationHilberg, F., Tontsch-Grunt, U., Baum, A., Le, A. T., Doebele, R. C., Lieb, S., Gianni, D., Voss, T., Garin‐Chesa, P., Haslinger, C., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244129 · Cited by 115
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
Sato, S., Shinohara, S., Hayashi, S., Morizumi, S., Abe, S., Okazaki, H., Chen, Y., Goto, H., Aono, Y., Ogawa, H., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0654-2 · Cited by 108
Redente, E. F., Aguilar, M., Black, B. P., Edelman, B., Bahadur, A. N., Humphries, S. M., Lynch, D. A., Wollin, L., & Riches, D. W. H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00304.2017 · Cited by 93
Self-citationHoffmann‐Vold, A., Tennøe, A. H., Garen, T., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.004 · Cited by 87
Endothelial dysfunction in systemic sclerosis
Altorok, N., Wang, Y., & Kahaleh, B. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000112 · Cited by 86
Fibrocytes in pulmonary fibrosis: a brief synopsis
Maharaj, S. S., Shimbori, C., & Kolb, M. R. J. (2013) · European Respiratory Review · doi:10.1183/09059180.00007713 · Cited by 84
Self-citationAlteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib
Bellamri, N., Morzadec, C., Joannes, A., Lecureur, V., Wollin, L., Jouneau, S., & Vernhet, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.061 · Cited by 74
Self-citationAkcora, B. Ö., Storm, G., Prakash, J., & Bansal, R. (2017) · Scientific Reports · doi:10.1038/srep44545 · Cited by 60
Eisen, T. G., Shparyk, Y. V., MacLeod, N. J., Jones, R. J., Wallenstein, G., Temple, G., Khder, Y., Dallinger, C., Studeny, M., Loembé, A., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9962-7 · Cited by 54
Rol, N., de Raaf, M. A., Sun, X., Kuiper, V. P., Bós, D. D. S. G., Happé, C. M., Kurakula, K., Dickhoff, C., Thuillet, R., Tu, L., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy186 · Cited by 51
Self-citationPiñol‐Jurado, P., Suárez‐Calvet, X., Fernández‐Simón, E., Gallardo, E., de la Oliva, N., Martínez‐Muriana, A., Gómez‐Gálvez, P., Escudero, L. M., Pérez-Peiró, M., Wollin, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0792-6 · Cited by 50
Self-citationNeovascularization in Idiopathic Pulmonary Fibrosis
Renzoni, E. A. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2403006 · Cited by 49
Management of Fibrosing Interstitial Lung Diseases
Maher, T. M., & Wuyts, W. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00992-9 · Cited by 48
Self-citationRuysscher, D. D., Granton, P. V., Lieuwes, N. G., van Hoof, S. J., Wollin, L., Weynand, B., Dingemans, A. C., Verhaegen, F., & Dubois, L. J. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.07.014 · Cited by 46
Self-citationEffect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model
Lee, H. Y., Hur, J., Kim, I. K., Kang, J. Y., Yoon, H. K., Lee, S. Y., Kwon, S. S., Kim, Y. K., & Rhee, C. K. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1339141 · Cited by 40
Kim, H.-Y., Kim, M., Kim, S., Joen, D., & Lee, K. (2018) · Molecules · doi:10.3390/molecules23081974 · Cited by 37
Cited by
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationThe natural history of progressive fibrosing interstitial lung diseases
Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00085-2020 · Cited by 293
Self-citationInhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model
Pei, Z., Qin, Y., Fu, X., Yang, F., Huo, F., Liang, X., Wang, S., Cui, H., Lin, P., Zhou, G., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102509 · Cited by 269
Spagnolo, P., Distler, O., Ryerson, C. J., Tzouvelekis, A., Lee, J. S., Bonella, F., Bouros, D., Hoffmann-Vold, A.-M., Crestani, B., & Matteson, E. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 259
Metadata
- Authors
- Wollin, L., Distler, J. H. W., Redente, E. F., Riches, D. W. H., Stowasser, S., Schlenker-Herceg, R., Maher, T. M., & Kolb, M.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-07-08
- Volume
- 54
- Issue
- 3
- Pages
- 1900161
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2956457443
- Cited by
- 296
- References
- 59
- FWCI
- 23.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.